Chronic exposure to low doses of MPTP. I. Cognitive deficits in motor asymptomatic monkeys

Brain Research

Volumn 519, Issue 1-2, 1990, Pages 122-128

  Schneider, J S ^a   Kovelowski II, C J ^a  

^a Global Neurosciences Institute   (United States)

Author keywords

1 Methyl 4 phenyl 1,2,3,6 tetrahydropyridine; Basal ganglia; Cognition; Dopamine; Frontal cortex; Monkey

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BASAL GANGLION; COGNITION; COGNITIVE DEFECT; DEMYELINATION; FEMALE; FRONTAL CORTEX; MALE; MONKEY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; VISUAL STIMULATION;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMAL; COGNITION; FEMALE; MACACA NEMESTRINA; MALE; MOTOR ACTIVITY; PATTERN RECOGNITION, VISUAL; REFERENCE VALUES; SUPPORT, NON-U.S. GOV'T;

EID: 0025346258     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-8993(90)90069-N     Document Type: Article

References (39)

1. Alpha-2 adrenergic mechanisms in prefrontal cortex associated with cognitive decline in aged nonhuman primates
2. Comparison of the effects of frontal and caudate lesions on delayed response and alternation in monkeys
3. 3H]spiperone binding
4. Visuospatial impairment in Parkinson's disease
5. Cognitive deficit caused by regional depletion of dopamine in prefrontal cortex of rhesus monkey
6. The partial dopamine receptor agonist terguride in the MPTP-induced hemiparkinsonian monkey model
7. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra byN-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
8. Primate model of parkinsonism: selective lesion of nigrostriatal neurons by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine produces an extrapyramidal syndrome in the rhesus monkey
9. Symptoms and behavioral features induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in an old Java monkey (Macaca cynomolgus fascicularis (Raffles))
10. Behavioral effects of selective ablation of the caudate nucleus
11. MPTP primate model of Parkinson's disease: a mechanographic and electromyographic study
12. Variability and functional recovery in theN-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of parkinsonism in monkeys
13. Abnormal influences of passive limb movement on the activity of globus pallidus neurons in parkinsonian monkeys
14. An electron microscopic study of MPTP-induced inclusion bodies in an old monkey
15. Selective delayed response deficits in Parkinson's and Alzheimer's disease
16. The effects of selective caudate lesions in infant and juvenile rhesus monkeys
17. Cognitive performance in early Parkinson's disease
18. N-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) causes destruction of the nigrostriatal but not the mesolimbic dopamine system in the monkey
19. Biochemical neuropathology of Parkinson's disease
20. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis
21. Cognitive deficits in the early stages of Parkinson's disease
22. Cognitive impairments associated with early Parkinson's disease
23. The ‘motor’ vs. ‘sensory’ enigma in Parkinson's disease
24. Altered tonic activity of neurons in the globus pallidus and subthalamic nucleus in the primate MPTP model of parkinsonism
25. 1 agonist SKF 38393, reverses parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset
26. Anti-parkinsonian activity of (+)-PHNO in the MPTP-treated common marmoset
27. Changes in local cerebral glucose utilization associated with Parkinson's syndrome induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the primate
28. Sensory and movement-related neuronal activity in different regions of the primate striatum
29. Dopamine deficiency in the cerebral cortex in Parkinson's disease
30. Selective loss of subpopulations of ventral mesencephalic dopaminergic neurons in the monkey following exposure to MPTP
31. Deficits in operant behaviour in monkeys treated withN-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)
32. Deficits in reaction times and movement times as correlates of hypokinesia in monkeys with MPTP-induced striatal dopamine depletion
33. Deficits in behavioral initiation and execution processes in monkeys with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism
34. Changes in the local cerebral metabolic rate for glucose in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) model of Parkinson's disease
35. Frontal lobe dysfunction in Parkinson's disease
36. Memory disturbance and the Parkinson syndrome
37. A Parkinson-like neurologic deficit in primates is caused by a novel 4-substituted piperidine